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Abstract
Purpose Given the long-term, although potentially fatal,
nature of prostate cancer, there is increasing observational
evidence for the reduction in disease progression and
mortality through changes in lifestyle factors.
Methods We systematically reviewed dietary, nutri-
tional, and physical activity randomized interventions
aimed at modifying prostate cancer progression and dis-
ease-specific mortality, including a detailed assessment of
risk of bias and methodological quality.
Results Forty-four randomized controlled trials of life-
style interventions, with prostate cancer progression or
mortality outcomes, were identified. Substantial hetero-
geneity of the data prevented a meta-analysis. The included
trials involved 3,418 prostate cancer patients, median 64
men per trial, from 13 countries. A trial of a nutritional
supplement of pomegranate seed, green tea, broccoli, and
turmeric; a trial comparing flaxseed, low-fat diet, flaxseed,
and low-fat diet versus usual diet; and a trial supplementing
soy, lycopene, selenium, and coenzyme Q10, all demon-
strated beneficial effects. These trials were also assessed as
having low risk of bias and high methodological quality (as
were seven other trials with no evidence of benefit). The
remaining trials were either underpowered, at high or
unclear risk of bias, inadequately reported, of short dura-
tion or measured surrogate outcomes of unproven rela-
tionship to mortality or disease progression, which
precluded any benefits reported being reliable.
Conclusion Large, well-designed randomized trials with
clinical endpoints are recommended for lifestyle modifi-
cation interventions.
Keywords Physical activity  Diet  Nutrition 
Randomized controlled trials  Prostate cancer  Systematic
review
Introduction
Prostate cancer is the most common cancer in men in the
Western world [1]. In the UK, for example, it accounts for
a quarter of newly diagnosed cancers [2] and one in eight
men will receive a prostate cancer diagnosis [3]. Prostate
cancer is often localized and grows slowly, so men may
live for many years with the disease. However, prostate
cancer may behave more aggressively and is an important
cause of morbidity and mortality [4]. Given the long-term
chronic, but potentially fatal, nature of the disease, there is
growing interest in low-toxicity interventions in the tertiary
prevention of morbidity and mortality due to prostate
cancer. This is of particular importance as noninvasive
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active surveillance, as treatment for localized disease,
becomes more widely implemented and increases in pop-
ularity as a strategy for reducing potential overtreatment
[5]. As the number of cancer survivors in the USA
increases beyond 13 million [6], the American Society of
Clinical Oncology highlights the need for clinician and
survivor to understand secondary prevention and lifestyle
modifications that could benefit their prostate, as well as
overall, health [7]. Observationally, poor diet, low levels of
physical activity, and obesity are thought to play an
important role in cancer, including the progression of
prostate cancer [8–13]. Higher levels of physical activity
have been associated with reduced rates of overall, and
prostate cancer-specific, mortality [14]. World Cancer
Research Fund International guidelines for cancer preven-
tion include being physically active for at least 30 min
every day, limiting consumption of energy-dense foods,
eating a variety of vegetables, fruits, wholegrains, and
pulses, and limiting consumption of red and processed
meats [9]. Published systematic reviews in the field have
tended to examine only one specific nutritional element,
such as soy isoflavones [15], or have not always focused
specifically on prostate cancer [16, 17]. Those that
explored the implications of diet and nutrition more
broadly often looked at risk of disease development, not
progression and mortality [18], or did not include physical
activity interventions [18, 19]. Systematic reviews with a
focus on physical activity failed to include diet and nutri-
tion interventions or restrict the population to prostate
cancer patients [20]. Where diet, nutrition, and physical
activity interventions have been reviewed, primary out-
comes were not progression or mortality, but measures
such as body weight [21], or all cancers and pre-invasive
lesions were included [22]. Additionally, some reviews
have not focused purely on randomized controlled trials
(RCTs), which introduces further potential for bias [18],
and study methodology and risk of bias were not always
assessed [16, 19].
We therefore conducted a systematic review of dietary,
nutritional, and physical activity interventions aimed at
modifying prostate cancer progression and mortality in
men with prostate cancer. We update and broaden the
scope of previous systematic reviews [15–22] and under-
take detailed assessment of risk of bias and methodological
quality.
Materials and methods
Search strategy
Studies were identified through a systematic search of the
following bibliographic databases from inception to July
2014: AMED, CINCH, the Cochrane library, Embase,
MEDLINE, and Web of Science. The search strategy
specified terms for RCTs, prostate cancer, dietary, nutri-
tional, or physical activity interventions, and surrogate or
clinical measures of prostate cancer progression or mor-
tality (see Supplemental Data for Medline search strategy,
Online Resource 1). Reference lists of all eligible full-text
articles and all relevant systematic reviews that were
identified were hand searched for additional studies.
Inclusion and exclusion criteria
To be eligible, studies had to be RCTs in men with prostate
cancer who were randomized to dietary, nutritional, or
physical activity interventions, which reported on surrogate
or clinical measures of prostate cancer progression or
mortality. Dietary or nutritional interventions were con-
sidered to be those that altered the intake of foods or
dietary constituents either directly (e.g., by giving vitamin
supplements) or indirectly (e.g., through nutrition educa-
tion). Physical activity interventions were those involving
any movement using skeletal muscles. RCTs that involved
a combination of dietary, nutritional, and physical activity
interventions were included. Outcomes were post-inter-
vention effects on recognized surrogate measures of pros-
tate cancer progression [Gleason score; prostate-specific
antigen (PSA)] and clinical measures of prostate cancer
progression (metastases, recurrence, disease-free survival,
or prostate cancer mortality). An additional outcome was
circulating insulin-like growth factor (IGF). We extracted
data on any adverse events that were reported. There were
no language restrictions. Commentaries and other related
documents were excluded unless they provided additional
data.
Data screening
All titles and abstracts were independently screened by two
of three reviewers (LHM, RP, and VL) using pre-defined
inclusion and exclusion criteria. Exact duplicates were
removed. Any abstracts meeting the inclusion criteria were
retrieved as a full article. These were then independently
considered for inclusion by two of the three reviewers
(LHM, RP, and VL). Any disagreements were resolved
through discussion, and if necessary, the third reviewer was
consulted. An additional 5 % of titles and abstracts were
triple-screened for accuracy (LHM, VL, and SQ).
Data extraction
All data were extracted by one reviewer (VL) and double-
extracted by a second (LHM or RP) using a specifically
designed data extraction form. Any disagreement was
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resolved by consulting the third reviewer. All extracted
data were then checked for a final time by the third
reviewer (LHM or RP). We extracted data on study char-
acteristics, methodological quality (based on seven design
and implementation questions), variables required for a
Cochrane risk of bias assessment [23], and our pre-speci-
fied primary and secondary outcomes. The quality criteria
assessed were: similarity of baseline characteristics and
prognostic indicators between randomized arms; reporting
of a power calculation and whether this sample size was
achieved; reporting of withdrawal numbers and reasons by
group; description of equal therapeutic time between
groups. The risks of bias criteria assessed were: reporting
of sequence generation; allocation concealment; blinding
of participants, personnel, and outcome assessors; com-
pleteness of outcome data; and selective outcome report-
ing. Descriptions of what classifies as high and low risk can
be found in Supplementary Table 1 (Online resource 2).
Published protocols and trial registries were additionally
searched, where available and when necessary, for further
methodological detail related to methodological quality
and risk of bias assessment. Authors were contacted if
further data were required. Authors of non-peer-reviewed
documents (such as conference abstracts) were contacted
for published peer reviewed data; where none were pro-
vided, these were not included in the main analysis, but the
description of the study included at the end of Tables 1 and
4.
Data analysis
Due to substantial heterogeneity across the studies in
relation to intervention design, delivery mode and out-
comes reported, formal pooling of the data by meta-anal-
ysis was not appropriate or possible. Therefore, a
qualitative synthesis of all studies in a narrative format was
undertaken.
The PRISMA statement was followed and adhered to
[24]. The protocol was registered with PROSPERO Inter-
national Prospective Register of systematic reviews, Ref:
CRD42014008701.
Results
Descriptions of studies
The search identified 12,037 titles and abstracts, of which
9,481 (79 %) papers that did not meet our inclusion criteria
and 2,344 (19 %) exact duplicates were removed. The
remaining full texts of 212 (2 %) papers were retrieved and
read in full; 44 RCTs reported in 54 papers met the
inclusion criteria (Fig. 1).
The characteristics of the included studies are summa-
rized in Table 1. The 44 RCTs that were eligible for
inclusion in our review were published between 2001 and
2014 and involved 3,418 participants from 13 countries: 26
from the USA [25–57], three in Australia [58–60], the
Netherlands [61–63], and the UK [64–66], two in Canada
[67, 68], and one in each of China [69], Czech Republic
[70], India [71–73], Japan [74], New Zealand [58], Norway
[75, 76], Sweden [77], and Switzerland [78]. Where mul-
tiple papers were identified for the same RCT, all refer-
ences are reported; however, data reported in multiple
publications was only extracted once. The median size of
the trials was 64 men (interquartile range 42–98, range
19–383).
The men had undergone a variety of treatments: radical
prostatectomy followed by implementation of the inter-
vention (n = 13 [26, 30, 33, 34, 40, 44, 45, 51, 61–63, 70,
78]) or the commencement of the intervention in men prior
to undergoing radical prostatectomy (n = 13 [25, 27–29,
32, 35, 39, 41, 42, 49, 53–56, 60, 74–76]); active surveil-
lance, active monitoring, or watchful waiting (n = 13 [29,
36–38, 43, 46, 48, 50–52, 57, 61, 62, 64, 77, 78]); hormone
therapy or androgen deprivation therapy (ADT) (n = 11
[26, 34, 45, 47, 58, 59, 65–69, 78–80]); external beam
radiotherapy or brachytherapy (n = 12 [26, 31, 33, 34, 40,
45, 51, 58, 61–63, 67, 78]); orchiectomy (n = 2 [69, 71–
73]); chemotherapy (n = 1 [78]); and cryotherapy (n = 1
[26, 34]). The majority of studies were parallel group
RCTs, with one (n = 31 [25, 27, 29–33, 35, 36, 38, 40, 43,
44, 46, 48–50, 53–59, 61, 64–66, 68–70, 72–78]), two
(n = 3 [37, 52, 60, 67]), or three intervention arms (n = 3
[39, 41, 42]) versus usual care or some other control group.
There were two dual arm parallel group RCTs without a
usual care or control group comparator [26, 34, 47] and one
three arm parallel group RCT without a usual care or
control group comparator [28]. Four studies had a cross-
over design, two with one intervention arm and a usual care
or control group arm [62, 63], one with two intervention
arms and no usual care or control group arm [51], and one
with three intervention arms and no usual care or control
group arm [45].
Excluded studies
Of the 212 texts read in full, 160 (75 %) were excluded.
Thirty-eight did not involve a diet, nutrition, or physical
activity intervention, and these included Ernst et al. [81],
Peng et al. [82], and Sternberg et al. [83]. Twenty-two did
not include prostate cancer progression or mortality as an
outcome, for example James et al. [84], Zhang et al. [85],
and Lee et al. [86]. Trials that only included a small pro-
portion of prostate cancer patients within their total sample
and had analyzed the data as a whole were excluded, for
Cancer Causes Control (2015) 26:1521–1550 1523
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example Hamilton-Reeves et al. [87] (8.6 % of the study
sample had prostate cancer) and Herna´andez et al. [88]
(‘‘patients with a biopsy negative for prostate cancer
comprised the principal study sample’’ p520). Figure 1
highlights all reasons for exclusion.
Quality of the evidence
Risk of bias
Overall, most of the included papers demonstrated high
risk of bias on the majority of criteria or failed to
adequately report how they had conducted the study on
these essential criteria (Table 2). For sequence generation,
half of the 44 trials were assessed as being unclear risk of
bias and 22 had low risk of bias. The corresponding fig-
ures were, respectively: 30 unclear, 14 low, for allocation
concealment; 22 high, five unclear, 17 low, for blinding of
participants; nine high, 28 unclear, seven low, for blinding
of personnel; and four high, 29 unclear, 11 low, for
blinding of outcome assessor. In contrast, for completeness
of outcome data 14 demonstrated high, three unclear, and
27 low risk of bias and for selective outcome reporting four
demonstrated high but 40 had low risk of bias. Of note,
Fig. 1 PRISMA flow diagram
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Table 2 Assessment of risk of bias
Sequence
generation
Allocation
concealment
Blinding of
participants
Blinding of
personnel
Blinding of
outcome
assessor
Completeness of
outcome data
Selective
outcome
reporting
Nutritional interventions
Kucuk et al. [53–56] ? ? - ? ? ?a ?
Bylund et al. [77] ? ? ? ? ? - ?
Ansari and Gupta [71–73] ? ? - ? ? ? ?
Beer% et al. [49] ? ? ? ? ? ? ?
Kumar et al. [50] ? ? ? ? ? - ?
Kumar et al. [41] ? ? - ? ? ?a ?
Higashihara et al. [74] ? ? - ? ? ? ?
Stratton et al. [37, 52] ? ? ? ? ? ? -
Vidlar et al. [70] ? ? ? ? ? ? ?
Margalit et al. [31] ? ? ? ? ? ? ?
Lazarevic% et al. [75, 76] ? ? ? ? ? - ?a,b
Nguyen% et al. [32] ? ? ? ? ? - -c
Stenner-Liewen et al. [78] ? ? ? ? ? ? ?
Chen et al. [69] ? ? ? ? ? ? ?
Wagner% et al. [28] ? ? ? ? ? ?a ?
Gee et al. [27] ? ? - - - ? ?
Freedland% et al. [25] ? ? ? ? ? ? ?
Paller et al. [26, 34] ? ? ? ? ? - ?
Complex nutritional interventions
Demark-Wahnefried% et al. [42] ? ? - - ? ? ?
Dalais et al. [60] ? ? ? ? ? ? ?
Vaishampayan et al. [47] ? ? ? ? ? - ?
Kranse et al. [62] ? ? ? ? ? - ?
Schroder et al. [63] ? ? ? ? ? ?a ?
Hoenjet et al. [61] ? ? ? ? ? - ?
Grainger et al. [45] ? ? -* - - ? ?
DeVere White% et al. [38] ? ? ? ? ? - ?
Li et al. [44] ? ? -* ? ?a ? ?
Oh et al. [51] ? ? ? ? ? ? ?
Aronson% et al. [36] ? ? -* ? ? ? ?
Kumar% et al. [50] ? ? - ? ? ? ?
Carmody et al. [40] ? ? -* ? ? - ?
Parsons et al. [43] ? ? -* ? ? ? ?
Aronson et al. [35] ? ? -* ? ? - ?
Wright et al. [29] ? ? -* - ? ? ?
Thomas% et al. [64] ? ? ? ? ? ? -
Bosland et al. [30] ? ? ? ? ? - ?
Nutritional and physical activity interventions
Ornish et al. [48, 51], Frattaroli et al. [46] ? ? -* ? ? ?a ?
He´bert [33] ? ? -* ? ? - ?
Bourke et al. [66] ? ? -* - ? ? ?
Bourke% et al. [65] ? ? -* - ? - ?a
Physical activity interventions
Segal et al. [68] ? ? -* - ? ? ?c
Segal% et al. [67] ? ? -* ? ? ? -
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Bosland et al. [30] and Stenner-Liewen et al. [78] were
assessed to have low overall risk of bias, and Kucuk et al.
[53–56], Beer et al. [49], Kumar et al. [50], Segal et al.
[68], Demark-Wahnefried et al. [42], Schroder et al. [63],
Thomas et al. [64], and Bourke et al. [66] were assessed to
have relatively low overall risk of bias.
Methodological quality
The methodological quality of the trials was variable;
although it was generally acceptable in the majority of the
RCTs, some scored very low (Table 3). In particular, only
15 RCTs reported that they had reached an adequately
powered sample size and reasons for withdrawals were
described for only 20 RCTs.
Interventions
The median intervention duration was 12 weeks [in-
terquartile range 4–26 weeks (6 months), range
3–260 weeks (65 months)].
Single-factor dietary interventions
Calcitriol (vitamin D3) The effect of calcitriol supple-
mentation up to 2 months prior to radical prostatectomy
was reported in three RCTs [27, 28, 49]. Men were ran-
domized in the three trials, respectively, to doses of 10 lg
vitamin D daily versus no supplement; 400 versus 10,000
versus 40,000 IU vitamin D3 daily; and 0.5 lg/kg calcitriol
daily versus placebo. In all three trials, there was little
evidence of an effect of vitamin D3 on change in total PSA,
IGF-I, cell apoptosis, or proliferation.
Lycopene Lycopene supplementation up to 6 weeks prior
to radical prostatectomy was investigated in two RCTs
reported in five publications [41, 53–56]. Men were ran-
domized in the two trials, respectively, to doses of 15, 30,
or 45 mg lycopene daily versus no supplementation and
15 mg lycopene versus usual care. No between-group dif-
ferences in PSA change [41, 53–56], IGF-I change [53–56],
or cellular response [41, 53–56] were observed. In a trial
assessed as having high or unclear risk of bias on six of the
seven criteria, where low risk of bias was only attributed to
selective outcome reporting, Ansari and Gupta [71–73]
randomized men, with advanced or metastatic disease, to
orchiectomy alone versus orchiectomy plus 2 mg lycopene
supplementation twice daily. A difference in change in
PSA between the groups at 24 months was observed
(p\ 0.001); fewer intervention men had a clinically raised
PSA indicating progression than the control arm
(p\ 0.05); there were fewer bone metastasis in the inter-
vention group (p\ 0.02), and prostate cancer mortality
was lower in the intervention group (p\ 0.001).
Pomegranate Three trials [25, 26, 34, 78] randomized
men to pomegranate extract supplements, one inmen for four
weeks prior to radical prostatectomy [25]; one for up to
18 months following radiotherapy, prostatectomy, hormone
therapy or ADT, or cryotherapy [26, 34]; and one following
radiotherapy, prostatectomy, hormone therapy or ADT,
chemotherapy, or watchful waiting for 28 days [78]. In men
randomized to 2 g of pomegranate extract daily (including
1.2 g of polyphenol), there was no difference in measures of
cell proliferation, progression, or change in PSA [25]. In the
studies that randomized men at a variety of TNM classifi-
cation of malignant tumors stages to pomegranate extract
following definitive treatment, no differences were observed
in median PSA doubling time or PSA change between
experimental versus control groups [26, 34]. The third trial,
which was assessed to have low risk of bias, found no
between-group differences in PSA change [78].
Table 2 continued
Sequence
generation
Allocation
concealment
Blinding of
participants
Blinding of
personnel
Blinding of
outcome
assessor
Completeness of
outcome data
Selective
outcome
reporting
Galvao% et al. [58] ? ? -* - - ? ?c
Cormie% et al. [59] ? ? -* - - ? ?c
Due to the nature of the interventions, we modified the Cochrane guidelines to separate blinding of participants and blinding of personnel; this
addressed the difficulty in blinding participants in some of the interventions considered. Each trial was given a low (?), high (-), or unclear (?)
risk of bias score for each dimension. Where a full paper was not available risk of bias was not assessed, as it was felt this would be a biased
assessment without full data available
Key: ? low risk of bias; - high risk of bias; ? unclear; * impossible to blind
% papers with protocols or trial registration (protocols were not accessed for the majority of studies)
a Not on all outcomes
b Information from protocol
c PSA reported but not pre-specified in protocol or trial registration
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Table 3 Methodological quality
Similar
baseline
characteristics
Similar
prognostic
indicators
Power
calculation
conducted
Power
sample size
reached
Withdrawal
numbers by
gp
Withdrawal
reasons by
gp
Equal
therapeutic
time by gp
Nutritional interventions
Kucuk et al. [53–56] ? ? ? ? ? - ?
Bylund et al. [77] - ? - ? ? - ?
Ansari and Gupta [71–73] ? ? ? ? ? ? ?
Beer et al. [49] ? ? ? ? - - ?
Kumar et al. [50] ? ? ? - ? - ?
Kumar et al. [41] ? ? - - ? ? ?
Higashihara et al. [74] ? ? - ? - - ?
Stratton et al. [37, 52] - ? ? ? ? ? ?
Vidlar et al. [70] ? ? - ? na na ?
Margalit et al. [31] ? - ? ? - - ?
Lazarevic et al. [75, 76] ? ? ? ? - - ?
Nguyen et al. [32] ? ? - - ? ? ?
Stenner-Liewen et al. [78] ? ? ? ? ? - ?
Chen et al. [69] ? ? ? ? - - ?
Wagner et al. [28] ? ? - ? ? ? ?
Gee et al. [27] ? ? ? - - - -
Freedland et al. [25] ? ? ? -a - - ?
Paller et al. [26, 34] ? ? ? ? - - ?
Complex nutritional interventions
Demark-Wahnefried et al. [42] ? ? ? ? ? ? ?
Dalais et al. [60] ? ? - - - - ?
Vaishampayan et al. [47] ? ? ? ? ? ? ?
Kranse et al. [62] ? ? ? - ? - ?
Schroder et al. [63] ? ? ? - ? ? ?
Hoenjet et al. [61] ? ? ? ? - - ?
Grainger et al. [45] ? ? - ? na na ?
DeVere White et al. [38] ? ? ? ? - - ?
Li et al. [44] ? ? ? ? ? ? -
Oh et al. [51] ? ? ? - ? ? ?
Aronson et al. [36] ? ? ? - ? ? ?
Kumar et al. [50] ? ? na ? ? ? ?
Carmody et al. [40] ? ? ? na ? ? -
Parsons et al. [43] ? ? - ? ? ? -
Aronson et al. [35] ? ? - ? ? ? ?
Wright et al. [29] - ? - ? - - -
Thomas et al. [64] -b ? ? ? ? - ?
Bosland et al. [30] ? ? ? - ? ? ?
Nutritional and physical activity interventions
Ornish et al. [48, 51], Frattaroli et al.
[46]
? ? - - ? ? -
He´bert [33] ? ? ? ? ? ? -
Bourke et al. [66] ? ? - na ? ? ?
Bourke et al. [65] ? ? ? ? ? ? -
Physical activity interventions
Segal et al. [68] ? ? ? ? ? - -
Segal et al. [67] ? ? ? ? ? - -
1536 Cancer Causes Control (2015) 26:1521–1550
123
Genistein (soy) The effect of genistein supplementation
was investigated in two studies [50, 75, 76]. In men ran-
domized to 30 mg genistein daily for three to six weeks
prior to prostatectomy, differences in favor of the experi-
mental, versus control, group were reported for percentage
change in PSA (p = 0.051), cellular response (p = 0.033),
and cell proliferation (p\ 0.001). However, the trial was
assessed as having high or unclear risk of bias on four of
the seven criteria, and it was assessed to have low risk of
bias for sequence generation and blinding of participants,
as well as selective outcome reporting [75, 76]. Compa-
rably, in a trial with relatively low risk of bias, in men
undergoing watchful waiting, randomization to 60 mg
genistein daily versus an isocaloric placebo for 12 weeks
had no impact on mean change in PSA [50].
Selenium Two RCTs investigated the effects of selenium
[37, 52] or selenium and silymarin [70] supplementation:
one in men with localized disease on active monitoring,
active surveillance, or watchful waiting supplemented with
200 or 800 lg selenium versus placebo for up to
60 months; and the other in men following prostatectomy
who were supplemented with selenomethionine (240 lg
selenium and 570 mg silymarin) or placebo for 6 months.
There were no between trial group differences in measures
of PSA in either trial.
Other nutritional interventions There was no evidence of
any effect of any of the following interventions: Qilan cap-
sules (consisting of astragalus, fenugreek, gynostremma,
pentaphyllan, and smilaz glabra) given for 4 weeks versus
placebo inmenwho had undergone hormone therapy orADT
and orchiectomy on PSA outcomes [69]; 50 mg of beta
carotene on alternate days (for an unreported duration) ver-
sus placebo in men undergoing radiotherapy on prostate
cancer mortality [31]; 800 mg of polyphenol E versus pla-
cebo daily for 3–6 weeks prior to undergoing prostatectomy
on changes in PSA, IGF-I, or Gleason score or on tissue
measures of cell proliferation, cell apoptosis, angiogenesis
[32]; or 2.4 g eicosapentaenoic acid daily versus no
intervention for 24 months in men who had undergone rad-
ical prostatectomy on PSA failure [74]. However, in men not
undergoing active treatment, 295 g of rye bread versus a
wheat bread control for 11 weeks resulted in increased cell
apoptosis (p\ 0.05) in the intervention group, although no
effect on change in PSA or IGF-I were reported. This trial
was assessed to have high or unclear risk of bias on four of
seven criteria, and low risk of bias was found for blinding of
participants and outcome assessors, as well as selective
outcome reporting [77].
Multiple factor dietary interventions
Isoflavones Three studies explored the effect of combi-
nations of isoflavones within individual supplements [30,
38, 39]. In a study assessed as being of low risk of bias,
Bosland et al. [30] found no effect on recurrence-free
survival of powdered soy protein (combining genistein,
daidzein, and glycitein) compared with calcium caseinate
given for 24 months in a population of men who had
undergone radical prostatectomy. Others found no effect of
combinations of isoflavones on PSA measures in men due
to undergo radical prostatectomy [39] or men undergoing
active surveillance for a period of 6 months [38]. However,
a trial assessed to have high to unclear risk of bias on four
of seven criteria, where only blinding of participants,
completeness of outcome data and selective outcome
reporting were assessed as low risk of bias, randomising
men awaiting radical prostatectomy to either 50 g of heat-
treated soy, or 50 g of heat-treated soy plus 20 g of linseed,
or placebo, found a difference in change in PSA between
the soy-only and the placebo group (p = 0.02) and a dif-
ference in change in free–total PSA ratio between the two
intervention groups (p = 0.007) and the soy-only and
placebo group (p = 0.01) [60].
Other complex nutritional supplement interventions
In an RCT of men undergoing active surveillance or
watchful waiting, a capsule containing pomegranate seed,
Table 3 continued
Similar
baseline
characteristics
Similar
prognostic
indicators
Power
calculation
conducted
Power
sample size
reached
Withdrawal
numbers by
gp
Withdrawal
reasons by
gp
Equal
therapeutic
time by gp
Galvao et al. [58] ? ? ? ? ? ? -
Cormie et al. [59] ? ? ? ? ? ? -
Seven design and implementation questions were posed; RCTs were scored as yes (?), no (-), or unclear (?) for each question. Where a full
paper was not available methodological quality was not assessed, as it was felt this would be a biased assessment without full data available
Key: ? yes; - no; ? unclear
a Sample size not reached by n = 1
b Not similar on baseline age
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green tea, broccoli and turmeric in a capsule versus placebo
given for 6 months was associated with a reduced rise in
PSA (p = 0.0008) and an increase in the percentage of
participants with stable PSA at 6 months (p = 0.00001).
This trial was reported to have relatively low risk of bias
[64]. Schroder et al. [63] randomized men undergoing
radiotherapy or radical prostatectomy to a supplement
consisting of soy, lycopene, selenium and coenzyme Q10.
The intervention was associated with improved measures
of PSA during follow-up, and was assessed to have low
risk of bias on five of seven criteria, however, unclear risk
of bias for sequence generation and blinding of outcome
assessors. Further to this, several trials of various combi-
nations of nutrients in a variety of populations of men with
prostate cancer observed no evidence for any differences
[45, 47, 51, 61, 62].
Low-fat diet combined with other nutritional ele-
ments Three studies combined low-fat diet with another
nutritional element [35, 42, 44]. Aronson et al. [35] ran-
domized men due to undergo radical prostatectomy to
4 weeks of a daily low-fat and fish oil diet versus a Wes-
tern diet, the trial was assessed to have high or unclear risk
of bias for five of seven criteria, and low risk of bias was
only awarded for sequence generation and selective out-
come reporting. No differences were noted in change in
mean PSA or change in mean IGF-I, but there was a
reduction in cell proliferation (p = 0.026). Li et al. [44]
compared a daily low-fat, high-fiber and soy protein (40 g)
diet with a standard recommended control diet given for
48 months in men who had undergone radical prostatec-
tomy. A difference was observed in IGF-I change between
the groups (p = 0.04); however, none was seen for change
in PSA. This RCT was reported to have unclear or high risk
of bias on four of seven criteria, and low risk of bias was
only awarded for sequence generation, blinding of outcome
assessors and selective outcome reporting. Demark-Wah-
nefried et al. [42] randomized men due to undergo radical
prostatectomy to flaxseed, low-fat diet, or flaxseed and
low-fat diet versus usual diet, over an average of 31 days.
The trial was assessed to have low risk of bias for five of
seven criteria, and blinding of participants and of personnel
were assessed to show high risk of bias; there was a change
in proliferation rate between the flaxseed only and control
groups (p = 0.0013) but no difference between apoptotic
rate, median change in PSA, or median change in IGF-I.
Aronson et al. [36] randomized men undergoing active
monitoring to a low-fat diet, which included 35 mg of soy
protein per day for 1 month, versus a Western diet but
observed no differences in mean change in PSA or mean
change in IGF-I between experimental and control groups.
Three RCTs included an educational element within
their complex nutritional intervention [29, 40, 43] but
found no consistent effects in men awaiting radical
prostatectomy or undergoing radiotherapy, active moni-
toring, or active surveillance on PSA or IGF-I outcomes.
Physical activity
Four RCTs reported a physical activity intervention,
resistance and/or aerobic training [58, 59, 67, 68], but
found no consistent effects in men who had undergone
hormone therapy, androgen deprivation therapy, or radio-
therapy on PSA-based measures of progression. One of
these four trials was reported to have relatively low overall
risk of bias [68].
Combination interventions
Four RCTS combined both a nutritional and a physical
activity element in their intervention [33, 46, 48, 57, 65,
66]. All of these implemented an aerobic or aerobic and
resistance training program in combination with a nutri-
tional element. There was no consistent effect in men who
had undergone radiotherapy, radical prostatectomy, active
surveillance, or were on ADT. Only one of these trials had
relatively low overall risk of bias [66]. Further information
about all studies can be found in Table 4.
Adverse events
A variety of adverse events was reported in the included
RCTs, and these most often included gastrointestinal
events, such as mild abdominal pain, constipation, diarrhea
and nausea; also reported were myalgia, including aches
and pains and fever like symptoms, such as chills.
Discussion
Among 54 papers reporting the results of 44 RCTs that
explored dietary, nutritional, and physical activity inter-
ventions in men with prostate cancer, there was a large
degree of heterogeneity with regard to intervention aims,
methods of implementation and outcomes, with the quality
of the research often being poor. Only three of ten studies
with the lowest risk of bias and highest methodological
rigor found a possible beneficial effect; a study in men
undergoing watchful waiting or primary active surveillance
suggested that a capsule containing pomegranate seed,
green tea, broccoli and turmeric improved PSA kinetics in
the intervention group compared to the control arm [64]. A
study randomising men due to undergo radical prostatec-
tomy to flaxseed, low-fat diet, or flaxseed and low-fat diet
versus usual diet, over an average of 31 days, demonstrated
a change in proliferation rate between the flaxseed only and
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Table 4 Primary outcomes and summaries of included papers
Author—
related
publications
Intervention type and
intervention duration
Prostate cancer stage
(where reported) and
treatment received
Systematic review outcomes
(intervention vs. control only)
Outcome
in
original
paper
Nutritional or dietary intervention (single factor)
Chen et al. [69] QiIan (astragalus, fenugreek,
gynostremma, pentaphyllan, smilaz
glabra) supplement, four capsules, three
times a day versus P (starch)
Hormone therapy/ADT: 100 %
Orchiectomy: 100 %
PSA: Change, baseline to 4 weeks; mean
(SD) I: 15.76 (11.22)–3.44 (3.9), C:
14.98 (11.66)–4.16 (3.88); p[ 0.05
between groupsd
Unclear
Stenner-
Liewen et al.
[78]
Pomegranate juice, 500 ml/day,
2,294 mg/l polyphenol gallic acid
versus P juice
%. T0, I: 0, C: 4. T1, I: 17, C: 17. T2, I:
17, C: 41. T3, I: 51, C: 31. T4, I: 15, C:
7, No, I: 55, C: 78. N1, I: 45, C: 22. M1,
I: 44, C: 18.
Watchful waiting: 28.7 %
Radiotherapy: 20.2 %
Prostatectomy: 15.9 %
Hormone therapy/ADT: 42.5 %
Radiation and prostatectomy: 15.9 %
Chemotherapy: 12.7 %
PSA: Progression (phase 1 day 1–28);
mean (%) I: 18 (38 %), C: 19 (41 %);
p = 0.83d
Primary
PSA: Stabilization (phase 1 day 1–28);
mean (%) I: 27 (56 %), C: 26 (57 %);
NSd
Primary
PSA: Response (phase 1 day 1–28);
[50 % mean I: 0 (0 %), C: 0 (0 %);
C30 % mean I: 3 (6 %), C: 1 (2 %);
NSd
Primary
Freedland et al.
[25]
2,000 mg of POMx powder, including
1,200 mg polyphenol daily versus P
matching pill with same administration
schedule
Due to undergo prostatectomy: 100 % PSA: Change in ratio of baseline to pre-
surgery; p = 0.443
Secondary
Cell proliferation; ki67 mean (SD), I: 0.60
(0.89), C: 0.76 (0.90) p = 0.164;
Secondary
Nf-KB mean (SD); I: 44.44 (35.47), C:
44.85 (37.88); p = 0.887d
Cell development progression; ps6 kinase
mean (SD); I: 46.10 (24.85),
C: 39.53 (26.50); p = 0.245
Paller et al.
[26, 34]
Pomegranate extract 1 g versus
Pomegranate extract 3 g daily
Radiotherapy: 53.45 %
Surgery: 51.55 %
Brachytherapy: 75.2 %
Hormone therapy/ADT: 27.65 %
Radiation and Prostatectomy: 11.9 %
Cryotherapy: 1.95 %
PSA: Doubling time, median difference;
I1: 6.9 months, I2: 5.3 months;
p = 0.554d
Primary
PSA: Objective response rates; % patients
I1: 2 %, I2: 2 %; p = NRd
Secondary
Progression-free survival (stable disease);
% patients I1: 78 %, I2: 82 %; p = NRd
Secondary
Progressive disease rates; % patients I1:
20 %, I2: 16 %; p = NRd
Secondary
PSA: Declining levels; ‘‘declining PSA
seen in 13 % patients’’ p = NR Paller
et al. [34]
Unclear
Gee et al. [27] Vitamin D analog 10 lg daily versus
observation
Localized: 100 %
Due to undergo radical retropublic
prostatectomy: 100 %
PSA: Change in total; diff between
groups; Day 15; I: 8.9, C: 10;
p = 0.397; Day 21; I: 8.3, C: 10.3;
p = 0.024; Off study; I: 11, C: 10.5;
p = 0.077; ITT; I: 9.9, C: 9.2;
p = 0.156e
Primary
IGF-I: Change, lg/10E6 platelets between
groups; Day 15; I: 0.433, C: 0.426;
p = 0.599; Day 21; I: 0.458, C: 0.435;
p = 0.413; Study end; I: 0.4, C: 0.419;
p = 0.682; ITT; I: 0.4, C: 0.418;
p = 0.743e
Primary
Change in level of intervention element,
ng/ml, within intervention group; Day 8
p = 0.219; Day 28 p = 0.148e
Secondary
Wagner et al.
[28]
Vitamin D3 doses of either 400, 10,000,
or 40,000 IU/day
Localized: 100 %
Due to undergo radical prostatectomy:
100 %
PSA: Change in serum, between groups;
p = 0.60; NB. PSA was lower in the
combined higher dose groups than
400 IU; p\ 0.02e
Secondary
Cell proliferation; Ki67, between groups;
p = 0.46e
Primary
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Table 4 continued
Author—
related
publications
Intervention type and
intervention duration
Prostate cancer stage
(where reported) and
treatment received
Systematic review outcomes
(intervention vs. control only)
Outcome
in
original
paper
Margalit et al.
[31]
Beta carotene (50 mg on alternate days)
versus control (P)
T1/T2, I: 88, C: 85. T4/N1, I: 3, C: 3. T3,
I: 7, C: 8. Missing, I: 2, C: 4
Radiotherapy: 100 %,
Brachytherapy: 30.3 %
External beam radiation: 78 %
Prostate cancer mortality—median FU of
10.5 years;
hazard ratio = 0.85, 95 % CI (0.49–1.50)
following adjustment
Primary
Nguyen et al.
[32]
Polyphenon E (800 mg daily) versus P Due to undergo surgery: 100 % PSA: taken at 3–6 weeks; Absolute
change in PSA mean (SD), ng/ml; I:
-0.66 (SD 2.56), C: -0.08 (SD 1.28);
p = 0.26; % decrease I: 58.3 %, C:
36.4 %; p = 0.15d
Secondary
IGF-I; Absolute change mean (SD), ng/
ml; I: -6.89 (20.97), C: -1.20 (21.82);
p = 0.53 decrease %; I: 54.2 %, C:
36.4 %; p = 0.25d
Secondary
Cell proliferation, % Ki67 mean (SD); I:
5.65 (9.47), C: 4.37 (6.11); p = 0.68d
Secondary
Cell apoptosis, % cleaved caspase-3 mean
(SD); I: 0.39 (0.57), C: 0.46 (0.64);
p = 0.29d
Secondary
Angiogenesis, n of microvessels mean
(SD); I: 22.43 (9.93), C: 23.04 (10.40);
p = 0.89d
Secondary
Decrease in Gleason score; I: 20.8 %, C:
8.3 %; p = 0.22e
Secondary
Lazarevic et al.
[75, 76]
Genistein (30 mg daily, 3–6 weeks prior
to surgery) versus Control (P)
1c—I: 52.2 %, C: 76.5 %
2a—I: 47.8 %, C: 23.5 % Lazarevic et al.
[76]
Localized: 100 %
Awaiting radical prostatectomy: 100 %
PSA; % change, mean (CI); I: -7.8
(-16.1 to 0.6); C: 4.4 (-5.0 to 13.9);
p = 0.051; Change in mean (CI), I: 7.9
(6.6–9.2), C: 8.3 (6.5–10.2); p = 0.655
Lazarevic et al. [76]d
Primary
Tumor response: androgen related
biomarkers (KLK4); Difference in
mean; p = 0.033
Primary
Cell cycle regulation G3 cells; difference
in expression (p27); p = 0.016
Primary
Cell proliferation (Ki67) G3 cells;
difference in expression; p\ 0.001
Primary
Cell apoptosis (BAX, BCL-2) G3 cells
difference in expression; BAX
p = 0.011; BCL-2 p = 0.125
Primary
Neuroendocrine tumor response (CgA);
difference in expression difference;
p\ 0.001
Primary
Higashihara
et al. [74]
EPA (2.4 g/day) versus control (no
intervention)
%. PT1, I: 9.38, C: 6.6. PT2, I: 68.75, C:
70. PT3[, I: 21.88, C: 23.3
Awaiting to undergo surgery—100 %
PSA: failurea, end of study; n (%)
participants; I: 4 (12.5), C: 8 (26.7)
p = 0.16d
Primary
Stratton et al.
[37, 52]
3 arms: 200 lg/day selenium versus
800 lg/day selenium versus control (P)
Localized: 100 %
Active monitoring/surveillance: 100 %
(2010)
Watchful waiting: 100 % (2003)
PSA: doubling time; median years; I:
6.98, I2: 8.45, C: 6.24
I1 versus control, p = 0.613
I2 versus control, p = 0.328
Primary
Vidlar et al.
[70]
Selenomethionine (570 mg silymarin,
240 lg selenium) v
P—Isomalt (250 mg), microcrystalline
cellulose (250 mg), hydroxypropyl
cellulose (10 mg)
Prostatectomy/surgery: 100 % PSA: Median change; After 6 months
PSA was unchanged in both groups
Secondary
Median change in intervention element,
selenium lmol/l; Change within both
groups from baseline to 6 months
p\ 0.05
Secondary
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Kumar et al.
[41]
15 mg/day lycopene versus 30 mg/day
lycopene versus 45 mg/day lycopene
versus control (no supplement)
Localized: 100 %
Due to undergo prostatectomy: 100 %
PSA: total, difference in mean; no
evidence of any difference in mean
p = 0.28 (all I arms versus C)
Primary
Cell proliferation: Ki-67; Mean % (SD)
post-intervention; I1: 2.63 (1.41), I2:
3.51 (1.43), I3: 3.64 (1.9), C: 4.22
(1.86); p = NRd
Primary
Beer et al. [49] Calcitriol (0.5 lg/kg/day) versus control
(starch)
%. T1c, I: 58.8, C: 45. T2, I: 0, C: 5. T2a,
I: 29.4, C: 30. T2b, I: 5.9, C: 15. T2c, I:
0, C: 5. T3a, I: 5.9, C: 0.
Due to undergo prostatectomy: 100 %
Cell apoptosis (BCL-2 and C-Myc); No
BCL-2 staining in cancer cells was
detected; 14 % of adenocarcinoma
stained positive for C-Myc; p = NRe
Primary
% PSA undetectable post surgically; I:
100 %; C: 84 %; p = NR
Secondary
Kumar et al.
[50]
Soy protein (60 mg genistein daily)
versus Control (standard American diet
with isocaloric)
Watchful waiting: 100 % Total PSA: Change, difference in mean
(SD), baseline to 12 weeks; no evidence
of any difference in mean; p = 0.96d
Primary
Free PSA: Change, difference in mean
(SD), baseline to 12 weeks; no evidence
of any difference in mean; p = 0.13d
Primary
Total testosterone: change in mean (SD);
baseline to 12 weeks; no evidence of
any difference in mean; p = 0.11d
Primary
Free Testosterone: Change in mean (SD);
baseline to 12 weeks; no evidence of
any difference in mean; p = 0.15
Primary
Ansari et al.
[71–73]
Orchidectomy plus lycopene (2 mg twice
daily) versus orchidectomy
Advanced/metastatic: 100 %
Bilateral orchiectomy and anti-androgen:
100 %
PSA: change in mean baseline, 6 and
24 months; Unclear reporting of
between-group differences. Change
within intervention group at 24 months;
p\ 0.001
Primary
PSA: clinical response; % with
progression; I: 7, C: 25; p\ 0.05
Primary
Bone metastasis; n (%) progression; I: 2
(7), C: 4 (15); p\ 0.02
Primary
Prostate cancer mortality; total death
n (%); I: 7 (13), C: 12 22); p\ 0.001
Primary
Bylund et al.
[77]
Rye bran bread (295 g/day) versus control
(wheat bread)
T2%, I: 70, C: 87.5, T3%, I: 30, C: 12.5
No active treatment: 100 %
PSA: change in mean baseline and
3 weeks; Unclear reporting of between-
group differences. No changes in
plasma levels of PSA were observed for
total or free forms of PSA
Secondary
IGF-I, ng/ml. Change in mean; baseline
and 3 weeks; Unclear reporting of
between-group differences. IGF-I
remained essentially unaltered in both
groups
Secondary
Cell proliferation (Ki67, P27); Mean rate,
baseline and 3 weeks; Unclear reporting
of between-group differences. Within-
groups Ki67 increased (p\ 0.05) and
p27 decreased (p\ 0.05)d
Primary
Cell apoptosis: TUNEL; Difference in
Mean % (SD), baseline to 3 weeks; No
between-group differences reported.
Significant increase in intervention
group I: 1.5 (1.3)–5.6 (3.1); p\ 0.05d
Primary
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Kucuk et al.
[53–56]
Lycopene (15 mg twice daily) versus
control (usual care)
Due to undergo prostatectomy: 100 % PSA: Change, difference in mean (SE);
pre to post-intervention; no evidence of
any difference in mean; p = 0.25
Primary
Cell apoptosis, (Bax), expression levels,
mean (SE); Malignant Bax; I: 1.05
(0.29), C: 0.68 (0.18); p = 0.33; Benign
Bax; I: 0.62 (0.1), C: 0.79 (0.11);
p = 0.28
Primary
Cell apoptosis (BCL-2), mean (SE);
malignant BCL-2; I: 0.54 (0.01), C:
0.51 (0.06); p = 0.59; Benign BCL-2;
I: 0.63 (0.04), C: 0.58 (0.04); p = 0.31
Primary
IGF-I, difference in mean; pre to post-
intervention; % change (SE); I: 28.8
(5.5), C: 29.9 (5.3) p = 0.88 Kucuk
et al. [56]d. Plasma levels decreased in
both groups, I: p = 0.0002, C:
p = 0.0003 Kucuk et al. [53–56]d
Primary
Nutritional or dietary intervention (multiple factor)
Thomas et al.
[64]
Oral capsule containing pomegranate
seed, green tea, broccoli, and turmeric
versus identical P
Watchful waiting: 40 %
Primary active surveillance: 60 %
PSA: Change; % rise, median (CI); I: 14.7
(3.4–36.7), C: 78.5 (48.1–115.5);
p = 0.0008d
Primary
PSA: stable % participants; After
6 months; I: 46, C: 14; p = 0.00001d
Secondary
Wright et al.
[29]
Calorie reduced diet of
1,200–2,000 kcal/day and\30 % daily
energy from fat. Nutritional and
behavioral teaching versus continued
normal diet
T1%, I: 90, C: 66.6. T2%, I: 10, C: 33.3
Active monitoring/surveillance—47 %
Due to undergo prostatectomy—53 %
IGF-I: % change; baseline to 6 weeks;
geometric mean. I: 17.0, C: 20.9;
p = 0.84 between groupse
Primary
Change in intervention element; Calories
consumed, % change; I: -46.6, C:
-11.3; p = 0.03 between groupse
Secondary
Bosland et al.
[30]
Beverage powder of soy protein isolate,
19.2 g, containing, 1.24 mg genistein,
0.78 mg daidzein, 0.11 mg glycitein
versus calcium caseinate, 19.8 g
T1c or T2: 100 %
Prostatectomy/surgery: 100 %
Recurrence-free survival; Median time to
recurrence; I: 31.5, C: 44; p = 0.62;
% recurrence; I: 27.2, C: 29.5; HR,
coefficient, 0.96 (0.53–1.72) p = 0.89d
Primary
Aronson et al.
[35]
Low-fat diet and fish oil supplement
(200 mg eicosapentaenoic acid and
367 mg docosahaxaenoic acid daily)
versus Western diet (40 % fat, 15 %
protein, 45 % carbs) (control)
Localized: 100 %
Due to undergo surgery: 100 %
IGF-I: Change, mean difference; pre- and
post-intervention; mean (SD), I: 8.8
(6.2), C: -0.4 (4.3); p = 0.25d
Primary
PSA: Change, mean difference; pre- and
post-intervention; mean (SD), I: 0.08
(0.4), C: -0.09 (0.3); p = 0.53d
Secondary
Cell proliferation, % decrease of Ki67; I:
32.2 %, C: NR; p = 0.026d
Secondary
Aronson et al.
[36]
Low-fat diet, 15 % kcal from fat, 30 %
kcal from protein, including 35 g soy,
55 % kcal from carbohydrates,
including 35 g fiber per day versus
Western diet
Active monitoring: 100 % PSA: Change at 4 weeks, mean (SD); I:
9.2 (2.7)–11.4 (5), C: 7.8 (1.5)–6.3
(3.6); p = 0.23d
Primary
IGF-I: Change at 4 weeks, mean (SD); I:
58 (16.4), C: 24 (9); p = 0.09d
Primary
DeVere White
et al. [38]
450 mg genistein, 300 mg daidzein and
other isoflavones daily versus 5 g/day
of inert cellulose (P)
Active monitoring/surveillance: 100 % PSA: % change, n (%); Increased, I: 14
(50 %), C: 17 (68 %);[20 % increase,
I: 6 (21.4 %), C: 7 (28 %); Stable/
reduced, I: 14 (50 %), C: 8 (32 %);
[20 % reduction, I: 3 (10.7 %), C: 1
(4 %); p = 0.29d
Primary
Relationship of isoflavones to PSA levels.
Intercept value (SE); Genistein: 0.0021
(0.0171); Daidzein: -0.0020 (0.0017);
Equol: 0.01388 (0.0435); p = 0.25d
Secondary
1542 Cancer Causes Control (2015) 26:1521–1550
123
Table 4 continued
Author—
related
publications
Intervention type and
intervention duration
Prostate cancer stage
(where reported) and
treatment received
Systematic review outcomes
(intervention vs. control only)
Outcome
in
original
paper
Kumar et al.
[39]
Isoflavones, 40, 60, 80 mg versus control
(usual care)
Localized: 100 %
Due to undergo prostatectomy: 100 %
PSA: change, difference in mean; pre to
post treatment, mean (SD); I1: 4.88
(2.9)–5.52 (2.92), I2: 6.12 (2.6)–6.73
(NR), I3: 5.08 (2.58)–5.16 (8.66), C:
5.48 (3.38)–5.12 (1.86); Between-group
p value = NR
Secondary
Cell proliferation. Mean Ki67%, mean
(SD); I1: 3.2 (2.25), I2: 4.11 (3.53), I3:
4.63 (2.67), C: 4.22 (1.86); p[ 0.05,
NS
Primary
Carmody et al.
[40]
Dietary advice (reduced meat, dairy,
increased veg, plant based diet) and
cooking classes versus control (wait-list
control)
Radiotherapy: 30.6 %
Surgery: 55.6 %
Seed implantation: 13.9 %
PSA: Kinetics, Log PSA, mean difference
baseline to 11 weeks, mean (CI); I:
0.032 (0.013–0.054) to 0.011 (-0.023
to 0.047), C: 0.038 (0.018–0.057) to
0.037 (0.009–0.065); p = 0.28e
Secondary
PSA: doubling time, mean difference in
months; baseline to 3 months, mean
(CI); I: 21.5 (12.8–66.8) to 58.5 (14.7–
?), C: 18.4 (12.1–39.2) to 18.7
(10.6–81); p = NRe
Secondary
Denmark-
Wahnefried
et al. [42]
Flaxseed-supplemented diet versus low-
fat diet versus flaxseed-supplemented
low-fat diet versus control (usual diet)
Due to undergo prostatectomy: 100 % Proliferation rate: Mean Ki67; mean (CI);
I1: 1.66 (1.13–2.64), I2: 2.56
(2.00–3.69), I3: 1.50 (1.05–2.65), C:
3.23 (2.42–3.92); I1 versus C:
p = 0.0013; I2 versus C: p = 0.661
Primary
Tumor apoptotic rate, n (%); 0 %: I1: 29
(74 %), I2: 26 (74 %), I3: 32 (89 %), C:
33 (84 %);[0–1 %: I1: 6 (16 %), I2: 5
(14 %), I3: 1 (3 %), C: 5 (13 %);
[1–2 %: I1: 4 (10 %), I2: 4 (12 %), I3:
3 (8 %), C: 1 (3 %); I1 versus C:
p = 0.880; I2 versus C: p = 0.730
Secondary
PSA: Change, median difference baseline
to follow up; median (CI); I1: 6.2
(4.8–7.7) to 6.4 (5–7), I2: 5.5 (4.6–6.7)
to 5.6 (3.9–6.7), I3: 5.9 (4.9–9.4) to 5.7
(4.9–8.6), C: 5.3 (3.7–5.8) to 4.9
(3.5–6.2); I1 versus C: p = 0.286; I2
versus C: p = 0.764
Secondary
IGF-I: Change, difference in median
baseline to follow up, median (CI); I1:
124 (115–148) to 119 (107–133), I2:
133 (109–150) to 123 (100–141), I3:
129 (110–148) to 125 (113–139), C:
128 (106–133) to 112 (98–128); I1
versus C: p = 0.174; I2 versus C:
p = 0.370
Secondary
Parsons et al.
[43]
Structured dietary education and
telephone based counseling. Targeted
increasing intake of vegetables,
wholegrains, beans/legumes versus
Control, printed material with standard
guidelines recommending five servings
of fruit and vegetables a day
Active monitoring/surveillance: 100 % PSA: Change, mean difference; baseline
to 6 months, mean (SD); I: 7.21 (4.14)
to 9.94 (12.9), C: 6.94 (6.55) to 6.88
(6.98); p = 0.29; PSA: change, median
difference baseline to 6 months, median
(range); I: 5.47 (3–17.2) to 6.39
(2.56–72.5), C: 4.85 (1.77–23) to 4.09
(1.58–24.5); p = 0.21d
Secondary
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Li et al. [44] Low-fat (15 % fat), high-fiber (18 g/
1,000 kcal) with 40 g soy protein daily
versus control (USDA recommender
diet)
%. T1c, I: 3.8, C: 7.1. T2a, I: 7.7, C: 14.3.
T2b, I: 7.7, C: 0. T2c, I: 50, C: 57.1.
T3a, I: 11.5, C: 14.3. T3b, I: 7.7, C: 0.
T3c, I: 11.5, C: 7.1
Surgery: 100 %
PSA: change; three participants had a
raised PSA; 0.5 at 12 months; 0.7 at
18 months; 0.4 at 4 years; All other
participants had PSA remaining at\0.2;
p = NR
Secondary
IGF: change, mean difference; baseline to
6 months, mean (SD); I: 260.4 (8.6) to
220.5 (7.9), C: 262.9 (8.6) to 259.5
(14.3); p = 0.04
Secondary
Grainger et al.
[45]
Lycopene 25 mg/day for 4 weeks versus
soy 40 g daily, versus lycopene and soy,
25 and 40 g daily
Radiotherapy (NR)
Surgery (NR)
Brachytherapy (NR)
PSA: Change, % with change
Prolongation compared with pre-
enrollment, n (%); I1: 13 (65 %), I2: 10
(50 %); p = NR; lower PSA at end of
study than at enrollment, n (%); I1:
n (25 %), I2: 9 (43 %); p = NR; NB.
Outcome data given for 8 week
intervention but needs to be handled
with caution as intervention at 8 weeks
is difficult to interpret due to being a
cross over design
Secondary
Prior to enrollment 12 men (30 %) who
were in the slowest doubling time; by
end of study this number had increased
to 19 men (48 %); p = 0.08
Secondary
IGF-I: Change; No significant changes
during the course of the study for either
group; p = NR
Secondary
Vaishampayan
et al. [47]
Lycopene 15 mg twice daily versus
lycopene 15 mg twice daily and soy
isoflavone 40 mg twice daily
%. absence of metastases, I1: 79, I2: 70
presence of metastases, I1: 21, I2: 30
PSA progression without hormone
therapy: 64.7 %
Hormone therapy/ADT: 35.2 %
PSA: rate of PSA riseb, difference in
mean. No between-group analysis
reported, only reported results by
treatment stratification
Primary
PSA stabilizationc; n (%) reaching
stabilization; I1: 35 (95 %), I2: 22
(67 %)d p = NR
Primary
Hoenjet et al.
[61]
Supplement, vitamin C (750 mg/day),
selenium (200 lg/day), vitamin E
(250 mg/day), coenzyme Q10
(2 9 100 mg/day) versus control (P)
Either: CT1-4Nx Mo (with no curative
treatment) or CT1-4 N ? Mo
Watchful waiting, radiotherapy,
prostatectomy: 62.5 %
No curative treatment: 37.5 %
PSA: Change, difference in mean (CI);
pre to post-intervention; I: 1.3 (1.2–1.4),
C: 1.1 (0.9–1.4); p = 0.67; NB.
Geometric means are reported from
nonparametric data. The outcome is
presented on change in log PSA scoresd
Primary
Kranse et al.
[62]
Verum, selenium (0.6 mg daily),
genestein (180 mg daily), daidzein
(120 mg daily), lycopene (30 mg daily),
margarine (20 mg daily) versus control
(P)
% total. T1 or T2, 83, Grades 1 or 2, 60.
Watchful waiting: 13.5 %
Radiotherapy: 16.2 %
Surgery: 70.3 %
PSA: total PSA slope; mean response;
0.024; p\ 0.001; Treatment effect;
-0.0018; p = 0.84d
Primary
PSA: doubling time, weeks, median (CI);
I: 44 (32–71), C: 41 (30–63); p = 0.84d
Primary
Schroder et al.
[63]
Dietary supplement (soy (62.5 mg),
lycopene (15 mg), selenium (128 mg),
Co Q10 (4 mg) daily versus Control (P)
Radiotherapy: 31 %
Prostatectomy/surgery: 69.4 %
PSA: slope, log2 serum total difference in
median (range); I1: 0.0009 (-0.008 to
0.014); I2: 0.0022 (-0.004 to 0.014);
p = 0.041; PSA: slope, non-
transformed difference in median
(range); I1: 0.0010 (-0.041 to 0.279),
I2: 0.0025 (-0.003 to 0.110);
p = 0.030d
Primary
PSA: doubling time, days; I: 1,150, C:
445; Doubling time changed by factor
of 2.6d
Primary
Total PSA: Change concentration;
Median (range); I: 0.10 (-2 to 17), C:
0.1 (-0.1 to -8); p = 0.076d
Primary
Free PSA: I: 0 (-0.1 to 4.5), C: 0 (0–1.4);
p = 0.988d
Primary
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Oh et al. [51] PC-SPES (3 capsules daily/960 mg) or
DES (3 mg daily)
%. Rising PSA only, I1: 22, I2: 14. Bone
metastases, I1: 41, I2: 57. Soft tissue
metastases, I1: 9, I2: 11. Bone and soft
tissue metastases, I1: 28, I2: 18.
Radiotherapy: 18 %
Surgery: 29 %
Radiation and Prostatectomy: 14.5 %
None: 38.9 %
PSA: decrease after 1st round of
treatment, % mean (range); I1: 80
(59.3–99.4), I2: 72 (63.3–78.2);
p = NRe NB. As reported in paper
Secondary
PSA: Time to progression; median n of
months; I1: 5.5, I2: 2.9d; p = NR
Secondary
PSA: Nadir after initial treatment, median
(range); I1: 3.0 (0.2–16.8), I2: 22.1
(2.5–907); p = NRd
Secondary
Dalais et al.
[60]
50 g HT soy or 50 g HT soy and 20 g
linseed daily versus P (pearled wheat
bread)
Due to undergo prostatectomy: 100 % Total PSA: Change, difference in mean
baseline to follow up, mean (SD); I1:
7.16 (3.23)–6.34 (3.05), I2: 6.31 (4.02)–
6.99 (3.24), C: 5.81 (3.7)–7.11 (4.23);
% change in Total PSA; I1: -12.7 %,
C: 40 %; p = 0.02f; p for I2 versus
C = NR
Primary
Free PSA: Change, difference in mean
baseline to follow up, mean (SD); I1:
0.69 (0.28)–0.74 (0.36), I2: 0.62 (0.26)–
0.65 (0.42), C: 0.64 (0.54)–0.63 (0.48);
p = NRe
Primary
PSA: Free/total ratio; Change in total
ratio; I1: 27.4 %, I2: -10 %, C:
-15.6 %; I1 versus C p = 0.01; I1
versus I2 p = 0.007e
Primary
Physical activity interventions
Galvao et al.
[58]
Resistance and aerobic training versus
control (education booklet)
%, T2—I: 62, C: 62, T3/T4—I: 38, C: 38
Radiotherapy/Hormone therapy/ADT:
100 %
PSA: Change, adjusted group difference
in mean change at 6–12 months,
mean(CI).; 6 months, 0.1 (-0.71 to
1.1); p = 0.687; 12 months, -0.3
(-1.4 to 0.8); p = 0.584
Secondary
Cormie et al.
[59]
Resistance and aerobic training versus
usual care
Hormone therapy/ADT: 100 % PSA: change, adjusted group differences
in mean change over 3 months, mean
(CI); 0.18 (-0.25 to 0.60); p = 0.410
Secondary
Segal et al.
[67]
Resistance training versus aerobic
training versus control (usual care)
%. stage 1, I1: 0, I2: 2.5, C: 0. Stage 2, I1:
77.5, I2: 72.5, C: 85.4. Stage 3, I1: 20,
I2: 22.5, C: 9.8. Stage 4, I1: 0, I2: 0, C:
2.4. Unassignable, I1: 2.5, I2: 2.5, C:
2.4
Hormone therapy/ADT: 61.2 %
Radiotherapy: 100 %
PSA: Change, mean difference (CI);
baseline to 24 weeks; I1: -1.75 (-3.01
to -0.51), I2: -2.14 (-3.34 to -0.94),
C: -3.29 (-4.46 to -2.11); I1 versus
C: 1.53 (-0.18 to 3.25); p = 0.09 I2
versus C: 1.14 (-0.53 to 2.82);
p = 0.181
Secondary
Segal et al.
[68]
Resistance training, 60–70 % max,
3 9 per week versus waiting list
% Stage I, I: 0, C: 0. Stage II, I: 48.8, C:
47.9, Stage III, I: 13.4, C: 18.1, Stage
IV, I: 20.7, C: 13.9. Unassigned, I: 17.1,
C: 20.8
Scheduled to receive ADT—100 %
PSA: change; I: 1.78 decrease, C: 5.40
increase; p = 0.31d
Secondary
Nutritional and physical activity combined interventions
Bourke et al.
[65]
Aerobic and resistance training combined
with healthy eating advice versus usual
care
Locally advanced: 80 %, Advanced:
20 %
Hormone therapy/ADT—100 %
PSA: change, mean at 12 weeks; I: 3.5, C:
4.6; Mean difference, unadjusted (CI):
O.6 (-0.6 to 1.8); p = 0.35; Mean
difference, adjusted (CI): 0.5 (-0.7 to
1.7); p = 0.41d
Secondary
He´bert et al.
[33]
Healthy diet (decrease meat and dairy,
increased veg and soy) and aerobic
exercise versus control (usual care)
Radiotherapy: 36.2 %
Surgery: 14.9 %
Radiation and Prostatectomy: 48.9 %
PSA: Change, difference in mean baseline
to 6 months, mean (CI); I: 0.87
(0.43–1.74) to 0.84 (0.42–1.68), C: 0.71
(0.33–1.54) to 0.78 (0.36–1.7);
p = 0.45d
Primary
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control groups; however, no difference between apoptotic
rate, median change in PSA, or median change in IGF-I
were noted [42]. Finally, in a trial that randomized men
undergoing radiotherapy or radical prostatectomy to a
supplement consisting of soy, lycopene, selenium and
coenzyme Q10, the intervention was associated with
improved measures of PSA during follow-up. It should be
noted that despite PSA being the most widely available,
and cited, biomarker for prostate cancer, taken alone it may
not be an appropriate surrogate marker of long-term
therapeutic benefit in prostate cancer trials, which has not
been proven to be a suitable replacement for a final survival
endpoint [89].
Of the remaining studies with low risk of bias; an RCT
randomising men, who were due to undergo radical
prostatectomy, to calcitriol or control reported no differ-
ence in cell apoptosis or rise in PSA [49]. A trial where
patients were randomized to 15 mg lycopene versus usual
care reported no between-group differences in PSA change,
IGF-I change, or cellular response. A study which scored
Table 4 continued
Author—
related
publications
Intervention type and
intervention duration
Prostate cancer stage
(where reported) and
treatment received
Systematic review outcomes
(intervention vs. control only)
Outcome
in
original
paper
Bourke et al.
[66]
Aerobic and resistance training combined
with healthy diet advice versus control
(usual care)
%. Advanced/metastatic, I: 24, C: 28
ADT—100 %
PSA: change, difference; baseline to
12 weeks, mean (SD); I: 3.32 (6.83)–
4.55 (8.74), C: 5.02 (10.2)–6.24 (13.6);
Group mean difference (CI); 0.01 (-2.2
to 2.2); greater increase in intervention
group, p = 0.61
Secondary
IGF-I: Change, difference; baseline to
12 weeks, mean (SD); I: 74.5 (21.5)–
78.3 (22.6), C: 77.6 (25.8)–79.4 (27.2);
Group mean difference (CI); 1.9 (-6.9
to 10.8); greater increase in intervention
group, p = 0.72
Secondary
Ornish et al.
[48, 57]
Frattaroli et al.
[46]
Aerobic exercise and vegan diet
supplemented with soy (58 g), vitamin
E (400 IU), selenium (200 mcg), fish
oil (3 g), vitamin C (2 g) daily versus
Control (usual care)
T1 or T2: 100 %
Active monitoring/surveillance: 100 %
Watchful waiting: 100 %
PSA: change, difference in mean baseline
to 12 months, mean (SD); I: -0.25
(1.2), C: 0.38 (1.3); p = 0.016d
Primary
PSA: Change, mean increase over
24 months, mean (SD); I: 0.88 (1.88),
C: 0.99 (2.09); p[ 0.05 Frattaroli et al.
[46]d
Secondary
PSA: change in velocity, ng/ml/years; I:
0.58, C: 0.50; p[ 0.05 Frattaroli et al.
[46]d
Secondary
Prostate cancer treatment undergone, n;
0–12 months, I: 0, C: 6; 13–24 months;
I: 2, C: 7; p = 0.005; Effect size (CI):
0.255 (0.053–0.437) Frattaroli et al.
[46]d
Primary
Unpublished data (not included in analysis)
Cipolla et al.
[80]
(Poster only)
Sulforaphane, 60 mg daily for 6 months,
followed by a 2 month wash out period
versus P (not stated)
No metastasis: 100 %
Prostatectomy: 37 %
Prostatectomy and RTE: 50 %
RTE and Hormone therapy: 12.8 %
PSA: Change, ng/ml, mean (SD); I: 0.099
(0.341), C: 0.620 (1.417); p = 0.03e
Primary
Nayan et al.
[79]
(Abstract only)
Lycopene (8 mg daily) versus follow-up
care only
Advanced/metastatic: 100 %
Hormone therapy/ADT: 100 %
Disease progression; progression to
hormone resistant cancer n (%); I: 4
(10 %), C: 18 (47.3 %); p = NR
Unknown
C control, CI 95 % confidence interval, HR hazard ratio, I intervention, NR not reported, NS not significant, P placebo, PSA prostate-specific
antigen, SD standard deviation, SE Standard error
a PSA failure: PSA values were more than 0.2 ng/ml on two consecutive measurements Higashihara et al. [74]
b Rate of PSA rise: PSA velocity. Rate of PSA change over a period of time (http://www.upmccancercenter.com/cancer/prostate/psaelevated.
cfm)
c PSA stabilization: for minimum of 3 months
d Number analyzed different to number randomized
e Number analyzed unclear
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low for all risk of bias, and also had excellent method-
ological quality, randomized participants to take pome-
granate extract supplements following radiotherapy,
prostatectomy, hormone therapy or ADT, chemotherapy, or
watchful waiting for 28 days, and found no between-group
differences in PSA change [78]. A complex isoflavone
intervention, with strong methodological vigor and low risk
of bias, resulted in no change in recurrence-free survival
between groups [30], similarly, a trial, with relatively low
risk of bias, assessing the effect of genistein supplemen-
tation on men undergoing watchful waiting were random-
ized to 60 mg genistein daily versus an isocaloric placebo
for 12 weeks, no impact on mean change in PSA was
reported [50]. It should be noted that these previous studies
support World Cancer Research Fund International guide-
lines which state ‘‘Don’t use supplements to protect against
cancer’’ [9]. One study, identified as being relatively low
risk of bias, which combined aerobic and resistance train-
ing with diet advice [66], reported no difference in PSA or
IGF-I outcomes. Finally, a resistance training intervention
in men due to undergo ADT concluded no change in PSA
[68], and this RCT was reported to have relatively low risk
of bias. Most of the other studies reviewed were assessed as
having high or unclear risk of bias, often with poor
methodological vigor, so it is not possible to draw any
conclusions from those studies.
This is the first systematic review, to our knowledge,
which has combined interventions of modifiable lifestyle
risk factors, with a primary outcome of prostate cancer
progression or mortality. This is clinically relevant as it is
unlikely that patients would make changes to a singular
lifestyle behavior [90]; instead, for example, a clinician
may recommend changes to diet alongside an increase in
physical activity. As the number of cancer survivors living
for longer increases [7], particularly for those with prostate
cancer who are turning to active surveillance [5], further
understanding of diet, nutritional, and physical activity
interventions is of great importance.
The review was systematic and comprehensive and had
no language restrictions. All papers were at least double-
extracted. Risk of bias and methodological quality were
assessed by at least two independent reviewers. This review
does have some limitations. The primary outcomes of the
review were not always reported as primary outcomes in the
papers. Thus, we relied on reported secondary outcomes and
the RCTs may not have been powered to detect differences
in these outcomes. Meta-analysis was not possible due to
heterogeneity of trial design, outcomes and statistical pre-
sentation; however, a qualitative synthesis was conducted.
The limited quality of most of the RCTs, and the possibility
of publication bias (which we were unable to formally assess
in the absence of a meta-analysis), restricted the definitive
conclusions that could be drawn.
Conclusion
The complex nature of dietary, nutritional, and physical
activity interventions, along with the slow-growing nature of
prostate cancer that causes difficulties in measuring long-
term clinically relevant change, makes research in this area
difficult. Poor quality, variability in methodology, incon-
sistency of results, and a variety of proxies for prostate
cancer progression make firm conclusions hard to draw. The
RCTs identified in our review were generally likely to be
underpowered, appeared to be at high or unclear risk of bias
and were often inadequately reported, intervened for only
short durations and followed-up men for surrogate outcomes
of questionable relationship to clinical outcomes. Such trials
are unlikely to have any clinical impact and should be
abandoned in favor of large, well-designed trials with end-
points that will impact on clinical practice. These findings
are in line with previous systematic reviews which con-
cluded that the impact of interventions could not be reliably
estimated due to limited, and low-quality, RCTs [18, 22].
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